Novel Risk Factors for Recurrent Biliary Obstruction and Pancreatitis After Metallic Stent Placement in Pancreatic Cancer

Overview

Journal Endosc Int Open

Specialty Gastroenterology

Date 2020 Nov 3

PMID 33140016

Citations 11

Authors

Tsuyoshi Takeda

Takashi Sasaki

Takafumi Mie

Takaaki Furukawa

Ryo Kanata

Akiyoshi Kasuga

Masato Matsuyama

Masato Ozaka

Naoki Sasahira

Affiliations

Soon will be listed here.

Abstract

Self-expandable metallic stents (SEMS) are now widely used even for patients with borderline resectable (BR) pancreatic cancer (PC), as neoadjuvant therapy has become common. Therefore, we conducted this study to evaluate safety of SEMS placement in the population including BR PC and to explore risk factors for recurrent biliary obstruction (RBO), pancreatitis, and cholecystitis. We retrospectively investigated consecutive patients with PC who received initial SEMS between January 2015 and March 2019. We compared time to RBO (TRBO), causes of RBO, and stent-related adverse events (AEs) according to resectability status. Univariate and multivariate analyses were performed to explore risk factors for TRBO, pancreatitis, and cholecystitis. A total of 135 patients were included (BR 31 and unresectable [UR] 104). Stent-related AEs occurred in 39 patients: pancreatitis 14 (mild/moderate/severe 1/6/7), cholecystitis 12, and non-occluding cholangitis 13. TRBO, causes of RBO, and stent-related AEs were not significantly different according to resectability status. Overall rate of RBO was higher in UR PC due to the longer follow-up period. Sharp common bile duct (CBD) angulation was an independent risk factor for short duration of TRBO. High pancreatic volume index and SEMS of high axial force were independent risk factors for pancreatitis, whereas tumor involvement to orifice of cystic duct was the only risk factor for cholecystitis. We demonstrated that SEMS can be safely deployed even in patients with BR PC. Sharp CBD angulation and high pancreatic volume index were identified as novel risk factors for RBO and pancreatitis, respectively, after SEMS placement.

Citing Articles

Potential of 6-mm-diameter fully covered self-expandable metal stents for unresectable malignant distal biliary obstruction: a propensity score-matched study.

Yamashige D, Hijioka S, Nagashio Y, Maruki Y, Fukuda S, Yagi S Clin Endosc. 2025; 58(1):121-133.

PMID: 39895273 PMC: 11837552. DOI: 10.5946/ce.2024.044.

Endoscopic ultrasound-guided hepaticogastrostomy and endoscopic retrograde cholangiopancreatography-guided biliary drainage for distal malignant biliary obstruction due to pancreatic cancer with asymptomatic duodenal invasion: a retrospective,....

Takahara N, Nakai Y, Noguchi K, Suzuki T, Sato T, Hakuta R Clin Endosc. 2024; 58(1):134-143.

PMID: 39188118 PMC: 11837547. DOI: 10.5946/ce.2024.031.

Computed tomography-based prediction of pancreatitis following biliary metal stent placement with the convolutional neural network.

Hamada T, Yasaka K, Nakai Y, Fukuda R, Hakuta R, Ishigaki K Endosc Int Open. 2024; 12(6):E772-E780.

PMID: 38904060 PMC: 11188753. DOI: 10.1055/a-2298-0147.

Outcomes of 6-mm diameter fully covered self-expandable metal stents for preoperative biliary drainage in pancreatic cancer.

Nakagawa H, Takeda T, Okamoto T, Mie T, Kasuga A, Sasaki T DEN Open. 2024; 4(1):e360.

PMID: 38601271 PMC: 11004548. DOI: 10.1002/deo2.360.

Impact of preoperative self-expandable metal stent on benign hepaticojejunostomy anastomotic stricture after pancreaticoduodenectomy.

Mie T, Sasaki T, Kobayashi K, Takeda T, Okamoto T, Kasuga A DEN Open. 2023; 4(1):e307.

PMID: 37900615 PMC: 10612468. DOI: 10.1002/deo2.307.

References

Siddiqui A, Mehendiratta V, Loren D, Kowalski T, Fang J, Hilden K . Self-expanding metal stents (SEMS) for preoperative biliary decompression in patients with resectable and borderline-resectable pancreatic cancer: outcomes in 241 patients. Dig Dis Sci. 2012; 58(6):1744-50. DOI: 10.1007/s10620-012-2482-z. View

Shimizu S, Naitoh I, Nakazawa T, Hayashi K, Miyabe K, Kondo H . Predictive factors for pancreatitis and cholecystitis in endoscopic covered metal stenting for distal malignant biliary obstruction. J Gastroenterol Hepatol. 2012; 28(1):68-72. DOI: 10.1111/j.1440-1746.2012.07283.x. View

Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M . Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019; 49(2):190-194. DOI: 10.1093/jjco/hyy190. View

Barenboim A, Lahat G, Geva R, Nachmany I, Nakache R, Goykhman Y . Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Eur J Surg Oncol. 2018; 44(10):1619-1623. DOI: 10.1016/j.ejso.2018.07.057. View

Shubert C, Bergquist J, Groeschl R, Habermann E, Wilson P, Truty M . Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database. Surgery. 2016; 160(4):1080-1096. DOI: 10.1016/j.surg.2016.06.010. View

Tsuboi T, Sasaki T, Serikawa M, Ishii Y, Mouri T, Shimizu A . Preoperative Biliary Drainage in Cases of Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgery. Gastroenterol Res Pract. 2016; 2016:7968201. PMC: 4736763. DOI: 10.1155/2016/7968201. View

Kawakubo K, Isayama H, Nakai Y, Togawa O, Sasahira N, Kogure H . Risk factors for pancreatitis following transpapillary self-expandable metal stent placement. Surg Endosc. 2011; 26(3):771-6. DOI: 10.1007/s00464-011-1950-4. View

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

Kubota K, Sato T, Watanabe S, Hosono K, Kobayashi N, Mori R . Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer. Dig Endosc. 2013; 26(1):77-86. DOI: 10.1111/den.12049. View

10.

Versteijne E, Vogel J, Besselink M, Busch O, Wilmink J, Daams J . Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018; 105(8):946-958. PMC: 6033157. DOI: 10.1002/bjs.10870. View

11.

Maruyama H, Shiba M, Ishikawa-Kakiya Y, Kato K, Ominami M, Fukunaga S . Positive correlation between pancreatic volume and post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2019; 35(5):769-776. DOI: 10.1111/jgh.14878. View

12.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

13.

Chawla A, Ferrone C . Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. Front Oncol. 2019; 9:1085. PMC: 6811513. DOI: 10.3389/fonc.2019.01085. View

14.

Miura S, Kanno A, Masamune A, Hamada S, Hongou S, Yoshida N . Risk factors for recurrent biliary obstruction following placement of self-expandable metallic stents in patients with malignant perihilar biliary stricture. Endoscopy. 2016; 48(6):536-45. DOI: 10.1055/s-0042-102651. View

15.

Wasan S, Ross W, Staerkel G, Lee J . Use of expandable metallic biliary stents in resectable pancreatic cancer. Am J Gastroenterol. 2005; 100(9):2056-61. DOI: 10.1111/j.1572-0241.2005.42031.x. View

16.

Isayama H, Yasuda I, Ryozawa S, Maguchi H, Igarashi Y, Matsuyama Y . Results of a Japanese multicenter, randomized trial of endoscopic stenting for non-resectable pancreatic head cancer (JM-test): Covered Wallstent versus DoubleLayer stent. Dig Endosc. 2011; 23(4):310-5. DOI: 10.1111/j.1443-1661.2011.01124.x. View

17.

Tempero M, Malafa M, Al-Hawary M, Asbun H, Bain A, Behrman S . Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(8):1028-1061. DOI: 10.6004/jnccn.2017.0131. View

18.

Suk K, Kim H, Kim J, Baik S, Kwon S, Kim H . Risk factors for cholecystitis after metal stent placement in malignant biliary obstruction. Gastrointest Endosc. 2006; 64(4):522-9. DOI: 10.1016/j.gie.2006.06.022. View

19.

Sasaki T, Kanata R, Yamada I, Matsuyama M, Ozaka M, Sasahira N . Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis. In Vivo. 2018; 33(1):271-276. PMC: 6364051. DOI: 10.21873/invivo.11471. View

20.

Cotton P, Eisen G, Aabakken L, Baron T, Hutter M, Jacobson B . A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010; 71(3):446-54. DOI: 10.1016/j.gie.2009.10.027. View